Proteolysis targeting chimeras (PROTACs) are emerging therapeutics for hematologic malignancies

Proteolysis targeting chimeras (PROTACs) are heterobifunctional small molecules that utilize the ubiquitin proteasome system (UPS) to degrade proteins of interest (POI). PROTACs are potentially superior to conventional small molecule inhibitors (SMIs) because of their unique mechanism of action (MOA...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:J Hematol Oncol
Hlavní autoři: He, Yonghan, Khan, Sajid, Huo, Zhiguang, Lv, Dongwen, Zhang, Xuan, Liu, Xingui, Yuan, Yaxia, Hromas, Robert, Xu, Mingjiang, Zheng, Guangrong, Zhou, Daohong
Médium: Artigo
Jazyk:Inglês
Vydáno: BioMed Central 2020
Témata:
Review
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7384229/
https://ncbi.nlm.nih.gov/pubmed/32718354
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13045-020-00924-z
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky